Boris Johnson Welcomes Novavax Trial Results On New Vaccine – ‘Regulators Will Assess It’

Boris Johnson Welcomes Novavax Trial Results On New Vaccine. image: No 10

Boris Johnson Welcomes Novavax Trial Results On New Vaccine – ‘Regulators Will Assess It’.

Boris Johnson said on Thursday, January 28, that it was good news the Novavax vaccine for Covid-19 had proved effective in trials in the United Kingdom. “Our medicines regulator will now assess the vaccine, which will be made in Teesside. If approved, we have 60 million doses on order,” Johnson said on Twitter.

The Novavax jab, which will be manufactured in Stockton-on-Tees, appears to be effective against both the original strain of coronavirus and a mutant strain first identified in Kent. It has also shown around 60 per cent effectiveness against the South African strain of coronavirus, which has been worrying scientists due to concerns vaccines may not work against it.

In the South African arm of the trial, where most cases of Covid-19 were the South African strain, the jab was 60 per cent effective in preventing mild, moderate and severe coronavirus among those without HIV. Including the HIV positive participants, whose immune systems are compromised, overall the protection was just over 49 per cent.

Health Secretary Matt Hancock said: “This is positive news and, if approved by the medicines regulator, the Novavax vaccine will be a significant boost to our vaccination programme and another weapon in our arsenal to beat this awful virus.”

The UK has secured access to 60 million doses of the new vaccine, which could be available in the second half of this year if it is approved by the medicines regulator.


Thank you for taking the time to read this news article “Boris Johnson Welcomes Novavax Trial Results On New Vaccine- ‘Regulators Will Assess It‘”. For more UK daily news, Spanish daily news and Global news stories, visit the Euro Weekly News home page.

 

FacebookTwitterRedditWhatsAppTelegramLinkedInEmailCopy Link
Go Back
Written by

Tony Winterburn

Share your story with us by emailing [email protected], by calling +34 951 38 61 61 or by messaging our Facebook page www.facebook.com/EuroWeeklyNews

Comments


    Leave a comment

    Your email address will not be published.